Kenneth Honn results 27
· Newest (Page 1/2, per page 25)
Author: Kenneth Honn ×Clear All Filters
Search Results
Tissue factor pathway inhibitor-2 (TFPI-2)—an underappreciated partaker in cancer and metastasisNARA Subscribed
The coagulation system is known to play an important role in cancer development and metastasis, but the precise mechanisms by which it does so remain incompletely understood. With this in mind, we provide an updated overview of the effects of TFPI-2, a protease inhibitor, on cancer development and metastasis. TFPI-2 interacts with the thrombin cascade and also employs other mechanisms to suppress cancer growth and disseminatio...
Cancer plasticity is now a recognized new hallmark of cancer which is due to disturbances of cell differentiation programs. It is manifested not only in various forms like the best-known epithelial-mesenchymal transition (EMT) but also in vasculogenic and megakaryocytic mimicries regulated by EMT-specific or less-specific transcription factors such as HIF1a or STAT1/2. Studies in the past decades provided ample data that cance...
The treatment of cancer patients with immune checkpoint inhibitors (ICI) (anti-CTLA-4, anti-PD-1, anti-PD-L1, combined therapy anti-PD-1/PD-L1 with anti-CTLA-4) has without doubt been a significant breakthrough in the field of oncology in recent years and constitutes a major step forward as a novel type of immunotherapy in the treatment of cancer. ICIs have contributed to a significant improvement in the outcome of treatment a...
Professor Lina M. Obeid (1955–2019)NARA Subscribed
Platelets and cancer angiogenesis nexusNARA Subscribed
EditorialNARA Subscribed
Work accomplishments—Isaiah J. FidlerNARA Subscribed
Inflammation and disease progressionNARA Subscribed